At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)
In Brief
A Phase 2 clinical trial evaluating Dasatinib for Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if BMS-354825 (dasatinib) can help to control CML in chronic phase. The safety of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedNov 2005
Primary CompletionMar 2025
TodayJul 2026
First PostedNov 16, 2005
Enrollment StartNov 8, 2005
Primary CompletionMar 14, 2025
TodayJul 2, 2026
Enrollment to primary: 19.3 yearsPosted 20.6 years ago
Interventions
Dasatinibdrug
Given PO